Herzliya, Israel

Orith Waisbourd-Zinman

This inventor holds 1 USPTO granted patent. Top assignee: Mor Research Applications Ltd.. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Orith Waisbourd-Zinman. Retrieved from https://idiyas.com/inventor/orith-waisbourd-zinman

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

Average Co-Inventor Count = 1.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Orith Waisbourd-Zinman: Inventor in Biliary Duct Treatment

Introduction

Orith Waisbourd-Zinman is an inventor based in Herzliya, Israel. Her work includes a patent describing an approach to treating damaged bile ducts by addressing glutathione (GSH) levels.

Latest Patents

Waisbourd-Zinman is associated with 1 patent, titled “Methods for Treatment of Damaged Biliary Duct.” The patent describes methods intended to elevate GSH levels, restore them to normal, or maintain normal levels in the biliary ducts. One disclosed approach involves locally treating damaged ducts by delivering an active agent into the bile duct lumen to promote GSH production or inhibit its degradation in biliary epithelial cells.

Career Highlights

Waisbourd-Zinman is associated with Mor Research Applications Ltd. Her patent focuses on a localized therapeutic strategy for damaged biliary ducts.

Collaborations

The available information identifies Mor Research Applications Ltd. as the company associated with Waisbourd-Zinman. No additional collaborators are specified in the provided details.

Conclusion

Orith Waisbourd-Zinman’s patent describes a targeted approach to biliary duct treatment centered on regulating glutathione levels.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…